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Abstract 
 A reduced testosterone concentration characterizes heart failure and independently 
predicts outcomes. Although testosterone replacement therapy may have non-cardiac-related 
therapeutic benefits in heart failure, whether reduced testosterone concentrations protect 
against adverse left ventricular remodelling (LV dilatation) is uncertain. I therefore evaluated 
whether surgical castration modifies LV dilatation following 6 months of daily injections of 
the β-adrenergic receptor (AR) agonist, isoproterenol (ISO) (0.015 mg/kg/day) to rats. The 
extent of LV dilatation and LV systolic chamber dysfunction were determined using both 
echocardiography and isolated perfused heart procedures. A load-independent measure of LV 
dilatation was determined from the volume intercept of the LV diastolic pressure-volume (P-
V) relationships. As compared to the saline vehicle-treated group, after 6 months of β-AR 
activation in sham-castrated rats, a marked right shift in the LV diastolic P-V relationship 
was noted with an increased LV volume intercept at 0 mmHg diastolic pressure (LV V0 in 
ml)(ISO=0.38 ± 0.02, Saline vehicle=0.30 ± 0.02, p<0.05). However, chronic β-AR 
activation did not alter LV systolic chamber function either in vivo (LV endocardial fractional 
shortening, echocardiography) or ex vivo (LV end systolic elastance). Although castration 
decreased body weight, castration failed to modify the impact of ISO on the LV diastolic P-V 
relationships or the LV volume intercept at 0 mmHg diastolic pressure (LV V0 in 
ml)(Castration ISO=0.35 ± 0.02, Castration saline vehicle=0.27 ± 0.03, p<0.05). In 
conclusion, castration does not influence the extent of LV dilatation induced by chronic 
adrenergic activation in an animal model where adverse LV remodelling precedes LV 
systolic chamber dysfunction. These data lend support for the notion that testosterone 
replacement therapy in heart failure may not produce adverse effects on the degree of cardiac 
dilatation. 
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Preface 
Despite impressive advances in the understanding and treatment of heart failure and 
cardiovascular disease during the last few decades, heart failure and cardiovascular disease 
remain pervasive in society, and prognosis once diagnosed is still incredibly poor. Thus, 
further understanding of the contributors to the development of heart failure, and possible 
identification of additional treatment options, remains of vital importance. 
 One aspect of cardiovascular disease which is still not fully understood is the 
progression to dilatated, decompensated heart failure; the haemodynamic and geometric 
changes which occur in such detrimental changes have been well documented, yet the 
underlying mechanisms and contributors are not yet fully understood. In that regard, there are 
gender differences in the form of left ventricular dysfunction developed by men and women, 
such that men have a greater tendency to develop dilatation in heart failure than women, and 
a greater degree of left ventricular systolic dysfunction; which is supported by other evidence 
such as gender differences in cardiac geometry and function in men and women at baseline, 
such that men have greater indices of dilatation and lower indices of function at rest before 
the development of any disease state. There are gender differences in the neurohumoral, 
specifically adrenergic, stimulation of the heart, such that male and female hearts respond 
differently to adrenergic stimulation and there are differences in the efficacy and outcomes of 
β-adrenergic receptor blockade in heart failure patients. 
As such, primarily in the last decade, there has been an increasing focus on the actions 
of testosterone due to the identified negative correlation of plasma concentrations of 
testosterone and worsening heart failure in men. This has led to an increasing focus 
supplementing these testosterone deficient men with exogenous testosterone in the hope of 
ameliorating their heart failure. However, there is controversy about the actions of 
testosterone such as stimulating increased dilatation; which, as yet, has not been confirmed or 
disproven in a chronic model of pump dysfunction or heart failure controlling for the inability 
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to follow individuals over the course of a lifetime, control for the severity and timing of 
pathological events, account for treatment differences or the impact of genetic or 
environmental factors on the heart, or control for the time between initiation of a pathological 
event and admission for therapy. In contrast, an animal model of the impact of castration on 
chronic β-adrenergic stimulation induced changes to cardiac geometry and function can 
control for all of those factors, and allow for a clear demonstration of the contribution of 
testosterone to dilatation. 
In Chapter 1 of the present dissertation, I provide a review of important scientific 
literature that describes the gender differences in normal function and geometry in humans, 
how this difference furthers in the development of congestive heart failure, and how gender 
differences in known contributors such as neurohumoral stimulation may be responsible. 
After which, I will argue in favour of performing the present study. In chapter 2 I will discuss 
the methodology employed. Following which, in chapter 3, I will discuss the results obtained. 
In chapter 4 of this dissertation, I will discuss these results in the context of the scientific 
literature described in chapter 1, highlight how these results potentially extend our knowledge 
of the field, underscore the strengths and limitations of the study, and suggest potential 
clinical and scientific implications for this body of work. 
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Chapter 1 
 
 
Introduction 
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1.1 Introduction 
 
Heart failure is a progressive clinical syndrome with a multitude of possible causes 
including coronary artery disease, hypertension, diabetes mellitus, obesity, rheumatic heart 
disease, genetic abnormalities and infections (Jessup et al 2003, Chatterjee and Massie 2007, 
Remme and Swedeberg 2001, Levy et al 2002, McMurray et al 2010, Cowie et al 2000, 
Mosterd et al 2001). Once diagnosed, the survival time in patients with heart failure is similar 
to that of some of the worst possible malignancies (Lenfant et al 1994, Stewart et al 2001, 
Hobbs et al 2004). The management of patients with heart failure is estimated to contribute 
toward a substantial portion of any country’s annual healthcare budget (Jessup and Brozena 
2003). 
Striking advancements have been made over the past three decades in our 
understanding of the pathophysiological mechanisms responsible for progressive heart 
failure. In this regard, distinct gender differences have been noted in these mechanisms. 
Indeed, men with heart failure typically have a poorer prognosis, a higher prevalence of 
systolic cardiac dysfunction, and a higher prevalence of cardiac dilatation relative to women 
(Regitz-Zagrosek and Seeland 2011, Konhilas et al 2010, Chin et al 1998, Adams et al 1999, 
Tamura et al 1999, Deschepper and Llamas 2007). Thus, the notion that testosterone has 
deleterious effects on the heart has evolved. Despite these gender differences, and the 
possibility that testosterone may have deleterious effects on the heart, recent evidence 
suggests that testosterone deficiency characterises heart failure in men (Jankowska et al 2006, 
Guder et al 2010, Kontoleon et al 2003, Pugh et al 2003, Wu et al 2011) and that testosterone 
deficiency heralds a poorer prognosis in heart failure (Jankowski et al 2006, Guder et al 
2010, Kontoleon et al 2003). Thus, testosterone replacement therapy has become a potential 
therapeutic target in heart failure (Malkin et al 2006, Caminiti et al 2009, Malkin et al 2010). 
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However, whether testosterone has beneficial or deleterious effects in heart failure is 
controversial. In light of the recent clinical trials designed to assess the effects of testosterone 
replacement therapy in heart failure (Malkin et al 2006, Hai-Yun et al 2011, Caminiti et al 
2009), the question of whether testosterone is beneficial or deleterious to the heart is of 
critical importance. In this regard, the important question is whether testosterone replacement 
therapy is unsafe in patients with heart failure. Hence, in the present dissertation I performed 
a study to further contribute toward our understanding of whether testosterone deficiency has 
beneficial, neutral or deleterious actions in cardiac disease. 
To assist the reader in understanding the arguments which led me to perform the 
current study and my choice of animal model of cardiac pathology, in the present chapter I 
will first provide an overview of the differences that characterise heart failure with either a 
reduced or a preserved systolic chamber function. I will subsequently describe the gender 
differences that exist in the pathophysiological mechanisms responsible for either a reduced 
or a preserved systolic chamber function. Consequently, I will describe the evidence to 
support or refute the notion that either testosterone has adverse effects on the structure and 
function of the heart and highlight the conundrum that currently exists with respect to the role 
of sex-steroid effects on the heart. I will subsequently lead the reader through the evidence to 
suggest that testosterone replacement therapy may benefit patients with heart failure and 
consequently summarise my arguments to suggest that further evidence is required to 
determine whether testosterone replacement therapy is safe in patients with heart failure. 
 
1.2 Cardiac dysfunction in heart failure 
 
Despite the diverse causes of the clinical syndrome, heart failure, from a 
pathophysiological perspective it has more recently been considered as being either 
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associated with a reduced or preserved ejection fraction (EF), where EF is a preload-
independent measure of systolic chamber function. At a more fundamental level, heart failure 
with a preserved EF may be considered as a primary disorder of filling (diastolic 
dysfunction), and heart failure with a reduced EF, may be considered as a primary disorder of 
emptying (systolic dysfunction) (Table 1.1). As gender differences in heart failure are often 
characterised by differences in the prevalence of heart failure with a reduced or preserved EF, 
in the following section I will briefly address the fundamental differences between heart 
failure with a reduced versus preserved EF. 
 
1.2.1 Heart failure with a preserved ejection fraction 
 
Heart failure with a preserved EF is a previously neglected, yet nevertheless common 
cause of heart failure (Vasan et al 1999), accounting for a significant proportion of morbidity 
and mortality (Zile et al 2005). Heart failure with a preserved EF, often called ‘diastolic heart 
failure’ to define the essential underlying functional abnormality, was first defined in 1988 to 
describe a subset of chronic heart failure patients characterised by concentric remodelling 
with a normal or even a reduced left ventricular (LV) filling volume, and an abnormal LV 
diastolic function (such as a slowed or delayed relaxation) due to an increased cardiac 
stiffness (Kessler et al 1988). Subsequently, the terms ‘diastolic dysfunction’ and ‘diastolic 
heart failure’ were recognised. In this regard. diastolic dysfunction was identified as a sub-
clinical syndrome associated with an abnormal mechanical property of the heart where the 
ability of the ventricular myocardium to return to a relaxed state is impaired. Diastolic heart 
failure was identified as a clinical syndrome with characteristic symptoms and signs of heart 
failure associated with a relatively normal systolic function but a reduced diastolic function 
5 
 
(Vasan et al 1999, Zile et al 2004, Zile et al 2005, Aurigemma and Gaasch 2004). Abnormal 
diastolic function is detected via measurements of the  
Table 1.1. Structural and functional changes in systolic versus diastolic heart failure 
(Summarized from the references listed below). 
  
Parameters Systolic heart failure Diastolic heart failure 
Important   
 Ejection fraction Decreased Normal 
 Gender Predominantly Male Predominantly Female 
 End-diastolic volume Increased Normal 
 Left ventricular shape Spherical Unchanged 
Unimportant   
 Left ventricular Mass Increased Increased 
 Left ventricular cavity size Increased Increased or normal 
 Mass/Cavity Decreased Increased 
 Wall thickness Decreased Increased 
 End-systolic stress Increased Normal 
 End-diastolic stress Increased Increased 
 End-systolic volume Increased Decreased or normal 
Aurigemma et al 2006, Chatterjee and Massie 2007, Van Heerebeek et al 2006, Dubourg et 
al 2008, Vasan et al 1999, Jessup et al 2003, Bursi et al 2006, McMurray et al 2010, Paulus 
et al 2007, Gaasch and Zile 2004, Sanderson et al 2007, Zile et al 2004, Aurigemma et al 
2004, Zile et al 2005, Gilbert and Glantz 1989. 
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diastolic ventricular pressure decline, and the relationships between diastolic pressure and 
volume, and ventricular wall stress and strain (Gilbert and Glantz 1989). These measures 
detect some of the characteristic features of diastolic dysfunction (Gilbert and Glantz 1989) 
and diastolic heart failure (Zile et al 2004), such as an increased filling pressure for any given 
volume due to a reduced cardiac compliance or an increased chamber stiffness and concentric 
remodelling (Chatterjee and Massie 2007) (Figure 1.1). Figure 1.1 depicts the basic 
functional and structural changes that occur in diastolic dysfunction, such as an increased LV 
wall thickness, reduced chamber size, and the impact of these changes on the LV pressure-
volume relationship. Although there are many known causes of diastolic dysfunction the 
exact mechanisms by which they cause the characteristic structural and functional changes 
are only superficially understood, possibly due to the diversity of the heart failure syndrome 
phenotype. For instance, diastolic dysfunction has been associated with changes in 
cardiomyocyte sarcomere anatomy (Chatterjee and Massie 2007), collagen regulation and 
crosslinking (Norton et al 1996, Norton et al 1997, Badenhorst et al 2003a), and myocardial 
calcium handling (Sordhal et al 1973). A reduced cardiac diastolic function, which translates 
into an increased ventricular filling pressure at a given filling volume (Figure 1.1), may result 
in an increased left atrial pressure, which subsequently leads to the clinical signs and 
symptoms of heart failure, such as pulmonary congestion and peripheral oedema. Although 
the pathophysiology of diastolic heart failure has generally been considered as separate from 
heart failure with a reduced EF, diastolic dysfunction may progress to systolic dysfunction 
(Yu et al 2002, Redfield et al 2003, Hein et al 2003). 
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Figure 1.1. Concentric remodelling in heart failure with a preserved ejection fraction. Panel 
A depicts a structurally normal heart; Panel B depicts a heart with isolated left sided 
concentric remodelling typical of heart failure with a preserved ejection fraction (depicting no 
mitral valve pathology); Panel C depicts the shift in the left ventricular (LV) diastolic 
pressure-volume relationship associated with diastolic dysfunction (D-Df); Panel D depicts 
the shift in the LV diastolic stress-strain relationship associated with D-Df. 
A) B) 
C) D) 
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1.2.2. Heart failure with a reduced ejection fraction. 
  
Heart failure with a reduced EF is well recognised form of heart failure (Zile et al 
2005, Chatterjee and Massie 2007, Aurigemma et al 2004, McMurray et al 2010). The 
fundamental functional abnormality of heart failure with a reduced EF is a reduced systolic 
chamber and myocardial function, which may or may not translate into a decrease in pump 
function (stroke volume and cardiac output). The reduction in EF may be attributed to 
decreases in myocardial cellular function, or an increased afterload produced by cardiac 
dilatation (increased cavity size and a reduced wall thickness which according the Law of 
LaPlace [Tension is determined by (pressure x radius)/(2 x, wall thickness)] increases wall 
tension or stress. Indeed, whereas heart failure with a preserved EF is defined by a left shift in 
the LV diastolic pressure-volume relationship and concentric remodelling (Figure 1.1), heart 
failure with a reduced EF is defined by a right shift in the LV diastolic pressure-volume 
relationship and eccentric chamber remodelling (Figure 1.2) (Zile et al 2005, Chatterjee and 
Massie 2007, Aurigemma et al 2004, McMurray et al 2010). Several possible mechanisms 
have been put forward to explain the reduction in wall thickness and dilatation in patients 
with systolic cardiac dysfunction. These include myocyte loss, myocyte dysfunction, 
inflammatory processes, alterations in the interstitium, and cardiomyocyte sarcomere 
disruption. 
 
1.2.3 Cardiac dilatation as both cause and consequence of cardiac dysfunction and 
failure.  
 
As myocardial systolic dysfunction progresses, stroke volume and cardiac output are 
maintained in-part as a consequence of fluid retention and increases in cardiac volume  
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Figure 1.2 Cardiac remodelling in heart failure with a reduced ejection fraction: Panel A 
depicts a structurally normal heart; Panel B depicts a heart with isolated left sided eccentric 
(dilatatory) remodelling typical of heart failure with a preserved ejection fraction (with no 
mitral valve pathology); Panel C depicts the shift in the left ventricular (LV) diastolic 
pressure-volume relationship during systolic dysfunction (S-Df); Panel D depicts the shift in 
LV systolic pressure-volume relationship during S-Df; Panel Ees depicts the shift in the LV 
systolic stress-strain relationship during S-Df. 
A) B) 
C) 
E) D) 
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preloads. In this regard, increases in cardiac filling volumes recruit the Frank-Starling effect 
and hence through an enhanced stretch of the myocardium, increase the force of contraction. 
However, the deleterious effect of increases in cardiac filling volumes is increases in filling 
(diastolic) pressures and hence in left atrial pressures. Increases in left atrial pressures 
contribute toward the development of pulmonary oedema (left heart failure) and the 
development of right heart failure. What was previously considered as an important 
compensatory change to maintain low filling pressures in the face of high filling volumes was 
the development of a right shift in the cardiac diastolic pressure-volume relationship, or 
cardiac dilatation. However, as indicated in the aforementioned discussion, cardiac dilatation 
results in an increased wall stress (afterload). A more contemporary notion is therefore that 
cardiac dilatation contributes toward progressive systolic chamber dysfunction in cardiac 
disease. What is the evidence to support this notion? 
A number of lines of evidence support the view that cardiac dilatation should be 
viewed as a cause and not just a consequence of cardiac systolic chamber dysfunction. 
Indeed, in both clinical (Gaudron et al 1993, Pfeffer et al 1992, Vasan et al 1997) and pre-
clinical (Veliotes et al 2005, Badenhorst et al 2003b, Gibbs et al 2004, Veliotes et al 2010) 
studies, cardiac dilatation has been noted to precede rather than follow left ventricular 
systolic chamber dysfunction and clinically relevant heart failure. Additionally, during 
treatment for heart failure, a reduction in cardiac chamber size and volumes is associated with 
improved cardiac outcomes, including survival (Doughty et al 1997, Sharpe and Doughty 
1998, Pfeffer et al 1992). Patients with an increased risk for developing cardiac dilatation 
also have an increased risk for developing heart failure or mortality after 6 months (de Kam 
et al 2002, Nestico et al 1985, Gadsboll et al 1990, Lee et al 1993, Foley et al 1995, Foley 
and Palfrey 1998). Furthermore, in the transition to heart failure in pressure overload states, 
cardiac chamber dilatation is more closely associated with a reduced systolic chamber 
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function than decreases in intrinsic myocardial systolic dysfunction (Norton et al 2002). The 
association of cardiac dilatation and cardiac outcomes in heart failure is sufficiently well 
established that measurements of cardiac chamber dimensions and thus the extent of cardiac 
dilatation have been added as risk predictors to guidelines for the management of heart failure 
(Hunt et al 2001). 
 
1.2.4. Identification of cardiac dilatation. 
 
Dilatation of the heart increases the internal dimensions of the ventricles, a change 
which is readily identified in a clinical setting by such techniques as echocardiography or 
magnetic resonance imaging (MRI). In this regard, cardiac end diastolic volume, which 
represents the maximum volume during the cardiac cycle, is employed as an index of 
chamber dilatation. However, as the heart is not an isolated system, and its function is altered 
by the physiology of the rest of the body (Gilbert and Glantz, 1989), cardiac end diastolic 
volume is dependent on such factors as preload, afterload, and heart rate. Indeed, an increase 
in volume preload will increase cardiac end diastolic volume (a greater filling will occur), an 
increased afterload will decrease systolic function, result in a reduced ventricular ejection and 
hence also increase end diastolic diameter, and a decreased heart rate will allow for a greater 
time for filling and hence similarly increase end diastolic volume. While such in vivo 
measures of cardiac end diastolic volumes or diameters are appropriate for a clinical setting, 
load- and heart rate-independent approaches to identifying cardiac dilatation provide more 
reliable data. In this regard, the volume intercept of the cardiac diastolic pressure-volume 
relationship excludes the impact of preload, afterload and heart rate on diastolic diameters. 
This concept will be further expanded on in the methods chapter of the present dissertation. 
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1.2.5 Neurohumoral stimulation as a major mechanism responsible for progressive 
heart failure with a reduced ejection fraction. 
 
Although there is little understanding as to what differentiates whether cardiac disease 
will progress to heart failure with a preserved or reduced EF, one possible factor that may 
determine the progression to one or the other form of heart failure is the impact of 
neurohumoral activation. In this regard, irrespective of the cause of heart failure, 
neurohumoral stimulation is a well-recognised determinant of progressive systolic cardiac 
dysfunction and subsequent heart failure (Yoshikawa et al 1996, Mann and Bristow 2005). 
Indeed, a number of findings underpin the neurohumoral hypothesis of progressive heart 
failure with systolic chamber dysfunction. Patients with heart failure have increased plasma 
concentrations of noradrenaline, relative to healthy individuals (Thomas and Marks 1978).  
Plasma concentrations of noradrenaline predict survival in patients with heart failure (Cohn et 
al 1984). Noradrenaline released from the failing myocardium may be approximately 50 
times greater than that of non-failing myocardium (Esler et al 1997). Increased plasma 
noradrenaline concentrations are associated with the severity of systolic chamber dysfunction 
and the degree of cardiac dilatation (Swedburg et al 1990, Anad et al 203, Francis et al 1993, 
Kluger et al 1982). Moreover, adrenergic receptor blockers reduce mortality, increase systolic 
chamber function and decrease cardiac chamber dimensions in patients with heart failure and 
a reduced systolic chamber function (Doughty et al 2004, Packer et al 1996, Packer et al 
2001, Herlitz et al 1999, Lechat et al 1997, Lechat et al 1999, Domanski et al 2003, Poole-
Wilson et al 2003, Flather et al 2005, Butler et al 2006, Hernandez et al 2009). In contrast, 
there is evidence to support a lack of beneficial effect of neurohumoral blockade on outcomes 
in patients with heart failure and a preserved EF (Hamdani et al 2009, Borlaug et al 2011).  
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At a preclinical level, there is also significant evidence to demonstrate that 
neurohumoral activation promotes the development of cardiac dilatation and systolic chamber 
dysfunction. In this regard, transgenic models of β2-adrenergic receptor over-expression (Gao 
et al 2003, Freeman et al 2001) and chronic adrenergic β-adrenergic receptor stimulation 
(Woodiwiss et al 2001, Badenhorst et al 2003, Veliotes et al 2005, Osadchii et al 2007) 
produce a cardiomyopathy with systolic chamber dysfunction and marked cardiac chamber 
dilatation. Hence, there is no question that neurohumoral activation mediates a reduced rather 
than a preserved systolic chamber function in progressive cardiac disease. 
 
1.3.0 Gender effects on cardiac structure and function. 
 
 There are a number of lines of evidence to indicate that gender differences exist in the 
structure and function of the heart. This evidence exists at a clinical level in patients with 
heart failure, at a community-based level in otherwise healthy individuals, at a preclinical 
level in basic cardiac structure and function and in animal models of cardiac dysfunction and 
heart failure. In the following section I will review this evidence. 
 
1.3.1 Gender differences in human heart failure. 
 
There is considerable evidence to indicate that marked gender differences occur in the 
pathophysiological features that characterise heart failure (Regitz-Zagrosek and Seeland 
2011, Konhilas 2010, Chin and Goldman 1998, Adams et al 1999, Tamura et al 1999, 
Deschepper and Llamas 2007). In this regard, consistent and striking differences have been 
reported in the proportion of men and women with heart failure with a reduced EF. A number 
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of these studies have been summarised in Table 1.2. In this regard, far more men develop 
heart failure with a reduced  
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Table 1.2 The proportion of men versus women included in heart failure studies.  
   Sample number % Men 
 
Article Study name Total Men Women 
 
Heart failure with a reduced left ventricular ejection fraction 
 
Average - 75% 
   Excluding ALLHAT - 77% 
 
Adams et al 1998. FIRST 471 359 112 76% 
 
Davis et al 2008. ALLHAT 506 315 191 62% 
 
Ghali et al 2003 BEST Study 2708 2115 593 78% 
 
Lewis et al 2007 Israel Nationwide Heart Failure Survey 1481 1045 436 71% 
 
Rathore et al 2002 Digitalis Investigation Group trial 6800 5281 1519 78% 
 Ghali et al 2002 MERIT-HF 3991 3093 898 78% 
 
Simon et al 2001. CIBIS II 2647 2132 515 81% 
Heart failure with either a reduced or normal left ventricular ejection fraction. 
  
Average 52.8% 
 
Chin and Goldman 1998. --- 179 89 90 50% 
 
Davis et al 2008. ALLHAT 910 511 399 56% 
 
Kalogeropoulos et al 2009. Health ABC study 258 124 134 48% 
 
Levy et al 2002. Framingham Heart Study 1075 527 548 49% 
 
Lewis et al 2007. Israel Nationwide Heart Failure Survey 2845 1603 1242 56% 
 
Senni et al 1998. --- 216 125 91 58% 
ALLHAT: Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial; BEST: Beta-Blocker Evaluation of Survival 
Trial; CIBIS II: Cardiac Insufficiency Bisprolol Study; FIRST: Flolan International Randomized Survival Trial; Health ABC: The Health, 
Aging, and Body Composition Study; MERIT-HF: Metoprolol Extended-release Randomized Intervention Trial. 
16 
 
EF as compared to women (Table 1.2, upper section). Importantly, these gender differences 
cannot be attributed to gender differences in the development of heart failure per se as an 
equal proportion of men and women develop heart failure (Table 1.2, lower section). As 
similar numbers of men and women develop heart failure, but more men develop heart failure 
with a reduced EF, it stands to reason, that more women and less men are prone to develop 
heart failure with a preserved EF. 
Not only are men more prone to developing heart failure with a reduced rather than 
preserved EF, but men with heart failure with a reduced EF have a worse outcome. Indeed, in 
the Flolan International Randomized Survival Trial (FIRST), consisting of 359 men and 112 
women with marked symptoms of heart failure, and a severe reduction in LV EF, the relative 
risk for death for male versus female subjects was 3.08 for subjects with a non-ischaemic 
aetiology (Adams et al 1998). Further, in the same study, the relative risk for death of male 
versus female subjects with an ischaemic aetiology was 1.64. Results from the Cardiac 
Insufficiency Bisprolol Study (CIBIS II), where 2132 men and 515 women with New York 
Heart Association (NYHA) class III and IV heart failure were analysed, women had 
significantly lower mortality rate relative to men (Simon et al 2001). Subsequent work has 
substantiated the notion that men with heart failure and a reduced EF have a greater mortality 
than women (Vasan et al 1999, O’Connor et al 2012). In contrast, women with heart failure 
and a preserved EF may have a greater mortality than men (Lewis et al 2007). Hence, there is 
some evidence that gender determines outcomes in heart failure, such that in heart failure 
with a reduced EF, men have greater mortality than women, while in heart failure with a 
preserved EF, women have a greater mortality than in men. 
There is also significant evidence to suggest that men and women demonstrate 
differences in the age of onset of heart failure. In this regard in the Framingham Heart Study, 
331 men and 321 women were diagnosed with heart failure at the respective average ages of 
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68.1 (SD:10.6) and 71.9 (SD:10.6) years (p<0.001 for the age difference) (Ho et al 1993). 
Similarly, in a community- based population study, 378 men, and 289 women were 
diagnosed with heart failure at the ages of 73 (95% CI of 12) and 79 (95% CI of 11) years 
respectively (p<0.001 for the age difference) (Roger et al 2004). Furthermore, as part of the 
OPTIMIZE-HF registry analysis (Fonarow et al 2007) heart failure with a reduced EF was 
diagnosed in 20118 people at an average of 70.4 (SD-14.3) years of age, of which, 68% were 
men, while heart failure with a preserved EF was diagnosed in 21149 people at an average 
age of 75.1 (SD-13.1) years, of which only 42% were men. Similarly, as part of the Israeli 
Nationwide Heart Failure Survey, heart failure with a reduced EF was diagnosed in 1481 
people at an average age of 71 (SD-12) years, of which 61% were men, while heart failure 
with a preserved EF was diagnosed in 1364 people at an average age of 73 (SD-12) years, of 
which, 52% were men (Lewis et al 2007). Hence, not only is there a gender difference in the 
form of heart failure that develops, but also a difference in the age of onset, such that men 
develop heart failure with a reduced EF at a younger age, while women develop heart failure 
with a preserved EF and are typically older. Could these gender differences in heart failure be 
attributed in-part to differences in the management or response to therapeutic agents in men 
and women with heart failure? 
 
1.3.2 Are there gender differences in the response to treatment in heart failure? 
 
It is now well-acknowledged that women are generally under-represented in clinical 
studies of β-blocker therapy and that few such studies appropriately stratify the analysis by 
sex to allow for the detection of a gender difference (Frankenstein et al 2012). Further, there 
is little evidence comparing gender effects on the impact of β-adrenergic receptor blockers in 
heart failure with a preserved versus reduced EF. In this regard, when stratified analyses are 
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available, data are either stratified only by sex (Ghali et al 2002, Ghali et al 2003, Simon et al 
2001), or by EF (Fonarow et al 2007, Van Veldhuisen et al 2009), but not by both. 
Nevertheless in an analysis of the CIBIS-II study in which only patients with a reduced LV 
EF were enrolled, women treated with the adrenergic receptor blocker bisoprolol had a lower 
(6% vs 12%, p=0.01) mortality relative to men, and this gender difference did not exist in the 
placebo group (13% vs 18%, p=0.10) (Simon et al 2001). Importantly, the relative risk of 
mortality for women compared to men with an underlying ischaemic aetiology was 0.63 
(95%CI 0.39-1.02, p=0.057), but there was no such sex relationship in non-ischaemic patients 
(p=0.734) (Simon et al 2001). In the BEST study (Ghali et al 2003), where patients with 
heart failure with a reduced EF were treated with the adrenergic receptor blocker bucindolol, 
women also had a reduced mortality relative to men (27% and 33% mortality respectively, 
p=0.02). Yet, in this study it was noted that the gender effect was confined to a non-
ischaemic aetiology, lower NYHA class (III vs IV), or non-diabetic patients (Ghali et al 
2003). Importantly, 64% of the men enrolled had an ischaemic aetiology, while 62% of the 
women enrolled had a non-ischaemic aetiology (p<0.001 for the difference) (Ghali et al 
2003). Further, Ghali et al (2002) performed a similar analysis on the MERIT-HF study 
population, in which 898 women and 3093 men with heart failure participated, and where the 
adrenergic receptor antagonist metoprolol was noted to decrease the relative risk of death in 
both men (18% relative to placebo, p=0.011) and women (21% relative to placebo, p=0.044). 
However, a direct comparison of the difference in survival between men and women was 
only performed in the placebo group, but did reveal that women had a significantly lower risk 
of death relative to men (0.63, 95%CI 0.43-0.91, p=0.015) (Ghali et al 2002). 
Although there is some evidence to suggest that gender differences may exist in the 
response to β-adrenergic blocker therapy in patients with a reduced EF, there is almost no 
evidence to show whether such sex differences characterise effects in heart failure with a 
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preserved EF. In this regard, in a small (n=66 patients) recent study (Farasat et al 2010), the 
effects of β-blocker therapy on rehospitalisation in patients with a preserved EF was 
evaluated, and the authors reported an increased risk of rehospitalisation in women but not 
men. 
 
1.3.3 Gender differences in basic cardiac structure. 
 
There are a number of lines of evidence to suggest that irrespective of gender 
differences in cardiac pathology and treatment, differences may exist between men and 
women in the basic structure of the heart. As such, differences in structure and function may 
in-part account for gender differences in cardiac function when pathology occurs or to the 
response to treatment. To that effect, as part of the Dallas Heart Study in 1183 men (44±9 
years of age) and 1435 women (45±9 years of age) whom were otherwise healthy, men had a 
greater LV mass (LVM) than women (191.7±44.4 vs 141.3±33.8 respectively; mean±SD; 
p<0.001), regardless of adjustment for body surface area (p<0.001) (Chung et al 2006). In 
addition, in 400 men and 400 women from the Multi-Ethnic Study of Atherosclerosis 
(MESA) an increased LVM and LV volume were noted in men relative to women (p<0.0001) 
regardless of indexing for height, body mass index (BMI), body weight, or body surface area 
(Natori et al 2006). In a community cohort over the age of 45 years, LV end diastolic volume 
was higher in men than in women regardless of adjustments for body surface area 
(p<0.0001), and LV end diastolic volume was positively correlated with age in men (r=0.13; 
p=0.003) but not in women (r=0.0; p=0.99) (Redfield et al 2005). Importantly, in that study 
(Redfield et al 2005) both LVM and LV relative wall thickness (an index of the degree of LV 
concentric remodelling) increased to a greater degree with age in women as compared to men 
(p<0.0001 for both). Thus, men appear to have a greater left ventricular volume, diameter, 
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and mass relative to women, but women appear to have a greater degree of LV concentric 
remodelling. Hence, men may be at risk of developing eccentric LV remodelling following a 
myocardial pathological insult, a change which may ultimately translate into heart failure 
with a reduced EF, whilst women may be at risk of developing concentric LV remodelling 
following a myocardial pathological insult, a change which may result in heart failure with a 
preserved EF.    
 
1.3.4 Gender differences in cardiac structure in animal models 
 
In human studies, gender differences in cardiac structure are confounded by an 
inability to follow individuals over the course of a lifetime, control for the severity and timing 
of pathological events, account for treatment differences or the impact of genetic or 
environmental factors on the heart, or control for the time between initiation of a pathological 
event and admission for therapy. In contrast, these factors can be readily controlled in animal 
studies. What is the evidence from animal studies that gender influences basic cardiac 
structure? 
Healthy male rats have been demonstrated to have a higher LVM (1.04±0.22 g; 
mean±SD) than female rats (0.67±0.13 g; p=0.01 for the difference), but with adjustment for 
body mass (2.6±0.6 g.g
-1
 vs 2.3±0.4 g.g
-1
; respectively), or for tibial length (0.22±0.07 g.mm
-
1
 vs 0.19±0.06 g.mm
-1
; respectively) these differences were eliminated (Forman et al 1997). 
However, LV end diastolic diameters are higher in male (7.7±0.7 mm; mean±SD) than in 
female (6.4±0.6 mm; p<0.001) rats, regardless of adjustment for body mass (p<0.003) and 
male rats have a reduced LV relative wall thickness, also regardless of adjustment for body 
mass (Forman et al 1997). Thus, in healthy rodents at least, gender differences in eccentric 
LV remodelling cannot be accounted for by differences in body size or LVM. In a study 
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conducted to evaluate the impact of aortic banding on the LV, LV diastolic diameters were 
also noted to be larger in the male sham-operated group (mean±SEM) (8.2±0.2 mm) as 
compared to the female sham-operated group (7.0±0.1 mm) (Douglas et al 1998). Hence, 
there is some evidence from animal studies to suggest that basic LV chamber sizes is larger in 
males as compared to females and that this is not entirely accounted for by differences in 
body size. 
 
1.3.5 Gender differences in basic cardiac function in human studies 
 
As described in sections 1.3.3 and 1.3.4, as compared to females, males have greater 
LV internal diameters, changes which are not necessarily determined by a greater body size. 
Hence, as compared to women, men are predisposed to eccentric LV changes. Do these 
geometric LV changes translate into functional differences? In this regard, a number of 
studies have provided the evidence to show that cardiac systolic chamber function is reduced 
in men as compared to women.  
In earlier studies no gender differences in left ventricular endocardial fractional 
shortening  were noted in 18 to 54 year old subjects but after the age of 55 years men had a 
lower LV endocardial fractional shortening (p<0.05) than women, even when adjusted for 
end systolic wall-stress (p<0.01) (Simone et al 1991). These data (Simone et al 1991) 
suggested that LV systolic function was lower in elderly men than in woman, but that the 
eccentric LV remodelling process, which results in a higher wall stress, could not explain 
these changes. However, subsequent studies suggested that the LV eccentric remodelling 
process may play a role. Indeed, in 102 men, and 141 women, LV EF (mean±SD) was noted 
to be lower in men (62±7%) as compared to women (64±6%; p=0.03 for the difference) 
(Celentano et al 2003). This occurred despite a higher LV mid-wall fractional shortening (an 
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index of myocardial function) in men (17.4±2.2) as compared to women (16.1±2.2; p=0.02 
for the difference) (Celentano et al 2003). As myocardial function appeared intact, these data 
(Celentano et al 2003) suggested that gender differences in LV EF are accounted for by the 
eccentric LV remodelling process. However, further studies did not support these findings. 
Indeed, in a larger study sample of 490 men, and 861 women in the Strong Heart Study, 
although men were reported to have a reduced LV EF (mean±SD) (63±9%) relative to 
women (66±8%; p=0.002 for the difference), and a decreased LV endocardial fraction 
shortening (34±7% for men, vs 36±6% for women; p=0.002), men also had a lower rather 
than higher LV mid-wall fractional shortening (17±3%) than women (18±2%; p=0.003 for 
the difference) (Bella et al 2006). Nevertheless, unlike the study showing a higher LV mid-
wall fractional shortening together with a reduced EF in men as compared to women, where 
LV volumes were also increased (Celentano et al 2003), in the Strong Heart Study population 
LV volumes were similar in men as compared to women (Bella et al 2006).  Moreover, in a 
large population based-study conducted in 1069 men, and 1115 women, where men had a 
reduced LV EF as compared to women (64.4±8.2% for men, vs 66.88±7.66% for women; 
p<0.001) in those less than 50 years of age the decreases in EF in males were not associated 
with parallel differences in LV systolic stress (Claessens et al 2007). 
However, all of the aforementioned studies were performed using echocardiography, 
which results in a reduced accuracy and precision of LV structural and functional changes as 
compared to MRI. What is the evidence for gender differences in function obtained from 
MRI-based studies? In this regard, MRI studies conducted in 400 men, and 400 women, also 
demonstrated that men have a lower LV EF than women (p<0.001), regardless of adjustment 
for body weight (p<0.001), body surface area (p<0.001), height (p<0.001), or BMI (p<0.001) 
(Natori et al 2006). In this regard, men also had higher LV volumes than women even with 
adjustments for differences in body size (Natori et al 2005). However, Natori et al (2006) 
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failed to report on gender differences in LV wall stress. Similarly, using MRI based 
measurements of LV structure and function, in the Dallas Heart Study, Chung et al (2006) 
demonstrated a decreased LV EF in men (70%) relative to women (75%; p<0.01). 
Subsequently, in an analysis of MRI-based measurements in the MESA population of 5004 
subjects without signs of cardiovascular disease, associated with increases in LV volumes, 
men were noted to have a lower LV EF as compared to women across all age groups from 40 
to 75 years of age (Cheng et al 2009). 
Therefore, in summary, current evidence consistently shows that as compared to 
women, men have a reduced LV EF, a finding that cannot be explained on the basis of 
differences in body size, but may to some degree be related to eccentric LV remodelling. 
These data suggest that the greater prevalence of heart failure with a reduced LV EF in men 
as compared to women (Table 1.2, upper panel) may be in-part a result of the pre-existing 
lower LV EF and eccentric LV remodelling in men before the development of heart failure. 
 
1.4. Gender differences in preclinical studies of cardiac disease. 
 
As the gender-differences that exist in human heart failure or in the human heart prior 
to the development of heart failure may be confounded by multiple variables including 
differences in the timing of the presentation of heart failure or its risk factors, the severity of 
the underlying pathology (e.g., severity of coronary artery disease), differences in the cause 
of the heart failure or cardiac function (e.g. coronary artery, hypertensive, diabetic, obesity-
related heart disease), variations in management strategies, etc, the question arises as to 
whether similar sex-differences exist in animal models of heart failure or cardiac disease 
where these factors are controlled for. What is this evidence? 
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1.4.1 Gender differences in preclinical studies of cardiac pathology attributed to 
pressure and volume overload. 
 
Cardiac pressure (such as occurs with hypertension or aortic stenosis), and volume 
(such as occurs with regurgitant valves or high output states) overload are well-recognised as 
discrete causes of cardiac systolic chamber dysfunction and heart failure. Pressure overload 
states increase the afterload that the heart must work against, resulting in a greater degree of 
LV concentricity, whilst volume overload increases the preload on the heart, resulting in a 
greater degree of LV eccentricity (Toischer et al 2010). Do animal studies provide evidence 
to support gender differences in the LV response to pressure or volume overload? 
With respect to pressure overload states, Douglas et al (1998) subjected both male and 
female weanling Wistar rats to supravalvular aortic banding for 20 weeks. Male rats clearly 
developed a greater degree of eccentric LV remodelling than females rats, such that male rats 
LV anterior and posterior wall thickness adjusted for body mass was lower than that of 
female animals and LV end diastolic diameters were higher in males as compared to females 
(Douglas et al 1998). However, male rats failed to develop a greater reduction in LV 
endocardial fractional shortening (Douglas et al 1998). In contrast, in a more recent study, 
male mice subjected to pressure overload developed a lower LV EF than female mice 
(Montalovo et al 2012). Moreover these gender-specific effects of pressure overload on LV 
EF were associated with parallel but inverse gender-specific changes in LV volumes 
(Montalovo et al 2012). 
With respect to volume overload states, Gardner et al (2002) compared the actions of 
an arterio-venous shunt on male and female Sprague Dawley rats. In this regard, a higher 
mortality rate was noted in male (24.5% mortality of the 200 male rats in the study) than in 
the female (2.5% mortality of the 40 female rats in the study) rats, and males, but not females 
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had evidence of LV eccentric remodelling (greater increase in LV end diastolic diameter), LV 
systolic chamber dysfunction and pulmonary congestion (lung weights) (Gardner et al 2002). 
Subsequently, Dent et al (2010, 2012) similarly demonstrated that as compared to female 
rats, male rats exposed to an arterio-venous fistula develop a reduced LV endocardial 
fractional shortening and an increased LV end diastolic pressure. 
In summary, consistent with data obtained in human studies, irrespective of whether 
pressure or volume overload states are studied, male as compared to female rodents, are 
susceptible to reductions in LV systolic chamber function and pathological evidence of heart 
failure in association with LV eccentric remodelling, which may or may potentially precede 
the functional changes (Douglas et al 1998).  
 
1.4.2 Gender differences in preclinical studies of myocardial infarction-induced 
cardiac remodelling. 
 
Myocardial infarction (MI) is a common cardiovascular event, often resulting in 
adverse cardiac remodelling with subsequent heart failure. There are clear gender differences 
in the degree of mortality, with male animals having a greater mortality than that of females 
(Cavasin et al 2006). However, are these gender differences in mortality in-part attributed to 
gender differences in adverse cardiac remodelling that occurs post-MI? 
 In this regard, following ligation of the left coronary artery, male rats developed a 
greater increase in LV diameter, an increased LV free wall area, and a greater right shift in 
the LV end diastolic pressure-volume relationship relative to female rats (Jain et al 2002). 
However, no comparisons of LV systolic function between genders were performed in that 
study (Jain et al 2002). Following ligation of the left coronary artery, Wu et al (2003) also 
demonstrated a greater increase in LV diastolic diameter in males as compared to females. 
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Although  LV EF was similar between male (40±1%) and female (41±1%) animals at two 
days post ligation, 28 days post ligation, males had a decreased LV EF (30±1%; p<0.05) 
while females had no significant decreases in LV EF (37±2%) (Wu et al 2003). Hence, 
gender-specific effects of MI on LV systolic chamber function cannot be attributed to 
differences in tissue damage produced by the MI, or to acute LV remodelling, but rather to 
the chronic remodelling process. Subsequently, Cavasin et al (2003, 2004) also demonstrated 
that after ligation of the left coronary artery, male rats have a higher rate of mortality as 
compared to female rats, and that male rats develop higher LV internal diameters, and a 
lower LV EF as compared to female rats. Thus, current evidence suggests that male rats are 
more susceptible than female rats to post-MI adverse LV remodelling, LV systolic chamber 
dysfunction and hence to a worse mortality. 
 
1.4.3 Gender differences in preclinical studies of neuro-humoral induced adverse 
cardiac remodelling and systolic dysfunction. 
 
As indicated in a previous section of the present dissertation (section 1.2.5), 
irrespective of the cause of heart failure, neurohumoral stimulation is a well-recognised 
determinant of progressive adverse cardiac remodelling, systolic chamber dysfunction, and 
subsequent worsening heart failure and poor outcomes in humans (Yoshikawa et al 1996, 
Mann and Bristow 2005). However, evidence for a gender-specific effect on the adverse 
effects of neurohumoral stimulation on the human heart are lacking, largely because it is 
impossible to control for confounding factors. The question therefore arises as to whether 
there is evidence for gender differences in adverse cardiac remodelling and systolic chamber 
function from animal-based studies? 
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Following excessive β2-adrenergic receptor expression in mice, although at 6 months 
of age no differences in the degree of LV dilatation were noted between male and female 
animals, at 9, 12 and 15 months of age while both genders had increases in LV diameters 
(p<0.01), only males had a decrease in LV wall thickness (p<0.05) and a concomitant 
increase in LV diameter divided by wall thickness) (an index of eccentric LV remodelling) 
(Gao et al 2003). Further, while LV endocardial fractional shortening decreased in both 
genders due to β2-adrenergic receptor overexpression, males developed a lower LV 
endocardial fractional shortening as compared to females at 9, 12, and 15 months of age (Gao 
et al 2003). While at 15 months of age, transgenic male animals suffered an 88% mortality, 
female animals suffered only a 44% mortality (p<0.001) (Gao et al 2003). In a further study 
of murine β2-adrenergic receptor overexpression, at 16 months of age, male transgenic 
animals had a higher (90%) mortality than females (50%, p<0.01), and transgenic males 
developed LV dilatation (LV end diastolic diameter indexed for body mass) earlier than 
females (p<0.001) (Thireau et al 2010). Furthermore, male transgenic mice had a higher 
prevalence of pleural effusions (71% in males vs 37% in females; p<0.05) and lung 
congestion (68% in males vs 37% in females; p<0.05), pathological signs of left heart failure, 
than females (Thireau et al 2010). Thus, a possible mechanism that may explain gender 
differences in adverse LV remodelling and systolic LV chamber dysfunction previously 
alluded to in aforementioned discussion, is a susceptibility of males to the adverse effects of 
adrenergic activation on the heart. 
 
1.5.0 Explanation for gender-differences in cardiac structure and function. 
 
An obvious question which arises from studies demonstrating gender differences in 
heart failure, cardiac pathology prior to the development of heart failure, and basic cardiac 
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structure and function, is whether these differences can be explained by variations in sex 
hormones and their actions on the heart. What is the evidence to suggest that sex hormones 
may explain gender differences in heart failure, cardiac pathology prior to the development of 
heart failure, and basic cardiac structure and function?  
 
1.5.1 Do differences in sex steroids explain gender differences in cardiac structure and 
function? 
 
The implications of the evidence for gender differences in cardiac structure and 
function reviewed in prior sections of the present dissertation is that either testosterone may 
have deleterious effects or that oestrogen may have beneficial effects on the LV eccentric 
remodelling process and hence on LV systolic chamber function. What is the evidence for 
these hypotheses? 
With respect to the possible deleterious role of testosterone on eccentric LV 
remodelling and LV systolic function, contradictory evidence exists. In favour of a 
deleterious effect of testosterone is the evidence that castration reduces the extent of increase 
in LV cavity dimensions associated with cardiac β2-adrenergic receptor over-expression (Gao 
et al. 2003) and aortic constriction (Montalvo et al. 2012) in mice. Furthermore, in male rats 
subjected to coronary artery ligation, castration maintained a greater LV EF, and reduced the 
degree of LV dilatation (Cavasin et al 2003). Further, when female rats subjected to coronary 
artery ligation received testosterone treatment, LV diameters increased and LV EF was 
reduced (Cavasin et al 2003). However, against a deleterious role of testosterone in mediating 
eccentric LV remodelling and LV systolic function, is the evidence that 
castration/orchiectomy worsens increases in LV diameter in rat models of doxorubicin-
induced LV dysfunction (Sun et al. 2011) and cardiomyocyte necrosis (Kang et al. 2012), or 
29 
 
produces no effect on LV internal diameter post-myocardial infarction (Nahrendorf et al. 
2003). With respect to the possible beneficial role of oestrogen on eccentric LV remodelling 
and LV systolic function, there is little evidence to support such a role. In this regard, 
oophorectomy failed to modify mortality, LV diameters or LV systolic chamber function in 
female mice with β2-adrenoreceptor over-expression (Gao et al 2003). Although there are 
many studies which investigate the progression and pathology of various models of heart 
failure and pump dysfunction, few include both male and female animals. Further, those that 
include both male and female animals do not appropriately stratify the analysis by gender. 
Hence, in summary there is no evidence to support a beneficial role of oestrogen as a 
potential mediator of gender differences in the LV eccentric remodelling process and hence 
in LV systolic chamber function. Moreover, the evidence in favour of testosterone mediating 
the gender differences in the LV eccentric remodelling process and hence in LV systolic 
chamber function is contradictory, with some studies suggesting a deleterious action, whilst 
others do not support this adverse effect. 
 
1.5.2 Interactions between adrenergic stimulation and gender hormones may in-part 
explain testosterone effects on cardiac structure and function. 
 
One possible mechanism that may explain gender differences in the LV eccentric 
remodelling process and hence in LV systolic chamber function, is through possible 
interactions with the adverse effects of sympathetic activation. Indeed, as reviewed in section 
1.2.5 sympathetic activation is a major determinant of LV dilatation and hence LV systolic 
chamber dysfunction. Evidence to suggest an interaction between adrenergic stimulation and 
gender or sex hormones is summarised in Table 1.3. In this regard, whether testosterone has 
beneficial or deleterious actions depends largely on whether baseline adrenergic function or 
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Table 1.3 Effects of testosterone on adrenergic stimulation of the heart.  
Article Model Main Outcome 
Gao et al 2003 Chronic - Mice Reduced mortality and morbidity in males, due to gonadectomy and thus 
testosterone removal. 
Sun et al 2011 Chronic - Male Rats Testosterone manipulation alters β-2 and β -3 adrenergic receptor expression. 
Engelhardt et al 1999 Acute – mice Reduced mortality and morbidity in males, due to gonadectomy and thus 
testosterone removal. 
Wang et al 2012 Acute - Male Rats Increasing testosterone concentrations reduced the noradrenaline release from the 
myocardium. 
Tsang et al 2008 Acute - Male Rats The presence of testosterone reduced the detrimental impact of ischaemic 
reperfusion combined with adrenergic stimulation. 
Vizgirda et al 2002 Acute – Rats Healthy male myocytes had a greater shortening response, and adrenergic receptor 
density than female myocytes. 
Tsang et al 2009 Chronic - Male Rats Testosterone replacement prevents changes in adrenergic responsiveness. 
Coulson and Cockroft 2011 Acute – Human The ß-blocking agent esmolol attenuated the rise in mean arterial pressure in men 
but not in women. 
Kang et al 2012 Acute - Male Rats Testosterone removal was associated with worse adrenergic induced cardiac 
outcomes. 
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pathological conditions are being considered. With respect to baseline function, relative to 
female rat cardiomyocytes, male rat cardiomyocytes have a greater adrenergic receptor 
density, and a greater contractile responsiveness to adrenergic stimulation (Vizgirda et al 
2002). Indeed, gonadectomy results in reduced myocardial adrenergic responsiveness, which 
is ameliorated by supplementation with physiological doses of testosterone (Tsang et al 
2009). Thus, the presence of testosterone is essential for maintenance of a normal adrenergic 
responsiveness in the heart. However, studies investigating the relationship between gender 
and adrenergic stimulation in pathology, report potentially beneficial or detrimental actions of 
male gender and testosterone depending on the pathology involved. What is this evidence? 
Testosterone reduces noradrenaline release from the myocardium induced by 
ischaemic-reperfusion injury (Wang et al 2012). These anti-adrenergic actions of testosterone 
may be beneficial as gonadectomised rats receiving physiological doses of testosterone 
develop a reduced myocardial infarct size in a mixed model of ischaemic-reperfusion and 
excessive adrenergic stimulation (Tsang et al 2008). After four weeks of volume overload 
induced via an arterio-venous fistula, in which eccentric LV remodelling was clearly detected 
in male but not female rats, a reduction of β1-adrenergic receptor mRNA expression was 
noted in male rats as compared to their controls, whilst female rats had no such reduction 
(Dent et al 2010, Dent et al 2011). Furthermore, β2-adrenergic receptor mRNA expression 
was increased in female hearts relative to control animals, but not in males and β1 and β2-
adrenergic receptor density and concentration was reduced in male hearts, whilst they were 
conversely increased in female hearts (Dent et al 2011). 
With respect to the role of testosterone in contributing toward the deleterious actions 
of chronic excessive adrenergic activation, as mentioned above, in two separate studies of 
transgenic mice with β2-adrenergic receptor overexpression, male mice have been noted to 
have a greater mortality, increased LV diameters and a reduced LV EF relative to the female 
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mice (Gao et al 2003, Thireau et al 2010). Furthermore, gonadectomy in male mice reduces 
mortality and LV diameters and increases LV EF (Gao et al 2003, Thireau et al 2010). 
Hence, at least in the context of excessive β2-adrenergic receptor over-activation, testosterone 
interacts with the adrenergic stimulus to enhance the adverse effects of adrenergic activation 
on adverse LV remodelling and LV EF. 
Lastly, as outlined in section 1.3.2, blockade of excessive adrenergic stimulation in 
men and women with heart failure and a reduced LV EF, appears to have different effects in 
men and women with women responding better than men. Further, β-blocker therapy might 
have differing actions on vascular function in men and women (Coulson et al 2011). In this 
regard, esmolol, a cardio-selective β1-adrenergic blocker, elicits a greater increase in systolic, 
diastolic, and mean arterial blood pressure in woman that it does in men (Coulson et al 2011). 
 
1.5.3 Testosterone deficiency and subsequent testosterone replacement therapy in 
human heart failure. 
 
Further evidence that castes light on the conundrum of whether testosterone has 
beneficial or deleterious effects in cardiac disease comes from recent evidence of 
relationships between heart failure and circulating testosterone concentrations and between 
circulating testosterone concentrations and outcomes. In this regard, an androgen deficiency 
in men with heart failure is well documented (Jankowska et al 2006, Guder et al 2010, 
Kontoleon et al 2003, Pugh et al 2003, Wu et al 2011). Furthermore, a lower plasma 
androgen concentration is an independent predictor of poor prognosis in men with heart 
failure (Volterrani et al 2012, Wu et al 2011). Indeed, an increased mortality was noted in the 
lower tertiles of both free (p=0.008) and total (p=0.003) plasma testosterone concentrations in 
175 men diagnosed with congestive heart failure (Wu et al 2011). Moreover, plasma free 
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testosterone concentrations are reduced in men with an LV EF less than 35% (5.8±2.7 pg.ml
-
1
; n = 50) as compared to those with an LV EF greater than 35% (6.9±3.3 pg.ml
-1
; n = 465; 
p<0.05) (Davoodi et al 2010). Further, Wu et al (2011) noted that both free and total 
testosterone plasma concentrations correlate with LV EF (r=0.31; p<0.01, and r=0.30; p<0.01 
respectively). In summary, in contrast to aforementioned data obtained in animal studies 
suggesting a deleterious action of testosterone on LV eccentric remodelling and LV EF, and 
data demonstrating a worse LV EF values in men as compared to women, findings which 
suggests that testosterone may have deleterious effects on the heart; data on testosterone 
concentrations in heart failure suggest that to maintain LV EF, ideal testosterone 
concentrations may be required. 
As a consequence of the findings demonstrating that testosterone deficiency in heart 
failure has adverse effects, several studies have investigated the effects of testosterone 
replacement therapy on LV structure and function in men with or without heart failure 
(Malkin et al 2006, Hai-Yun et al 2011, Caminiti et al 2009). These studies have nevertheless 
produced contradictory results. In this regard, testosterone replacement therapy given for 12 
months to males with heart failure increased LV internal length (Malkin et al 2006) and 
testosterone administration for 1 month to healthy males increased LV end systolic diameter 
(Chung et al 2007). However, 12 weeks of long acting testosterone supplementation did not 
alter LV end diastolic diameter or improve LV EF in men with congestive heart failure 
(Caminti et al 2009). 
Although unlikely to produce direct benefits to the heart, testosterone replacement 
therapy may nevertheless produce indirect benefits to cardiac function in heart failure. 
Indeed, testosterone supplementation may improve vascular resistance in either healthy men 
or men with heart failure (Pugh et al 2003, Malkin et al 2006) a finding that could translate 
into long-term benefits in heart failure through reductions in LV afterload. The ability of 
34 
 
testosterone to produce coronary vasodilation has also been well described (Jones et al 2004, 
Malkin et al 2010) and this may similarly translate into benefits in heart failure by improving 
myocardial blood supply. 
Testosterone replacement therapy in men with heart failure may also have a number 
of non-cardiac benefits. Indeed testosterone replacement therapy may improve exercise 
capacity and functional strength of the body as a whole by altering lean muscle mass, 
strength, and endurance (Malkin et al 2010, Caminti et al 2009). In this regard, 12 weeks of 
long acting testosterone supplementation increased peak oxygen consumption (13.4±4.4 
ml.kg
-1
 per min, to 16.3±1.7 ml.kg
-1
 per min; p<0.05), peak exercise workload (78.3±16.0 
watts, to 88.2±18.7 watts; p<0.05), and maximum voluntary contraction of leg muscles 
(116.7±26.3 Nm, to 135.6±21.2 Nm; p<0.05), while placebo administration produced no such 
changes (Caminti et al 2009). Furthermore, 12 months of testosterone supplementation in 
men with heart failure resulted in increased shuttle walking distances (p<0.006) indicating an 
increased exercise capacity, as well as an increased dominant handgrip strength (p=0.04) 
(Malkin et al 2006). 
Hence, although there is no apparent benefit to the heart, there are a number of 
possible reasons to treat hypogonadal male, heart failure patients with testosterone. 
Nevertheless, there are concerns about the risks of such treatment. Indeed, testosterone may 
increase the risk for cardiovascular disease in men, by contributing toward the metabolic 
syndrome, type II diabetes mellitus, abnormal lipid profiles, and atherosclerosis (Jones et al 
2010, Traish et al 2009a, Traish et al 2009b, Traish et al 2009c, Rhoden and Morgentaler 
2004). Moreover, testosterone therapy may result in polycythaemia, and either benign or 
malignant prostatic hyperplasia (Rhoden and Morgentaler 2004). Furthermore, as has been 
discussed in aforementioned sections and will be summarised in the subsequent section, there 
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is still no resolution as to whether testosterone contributes toward LV dilatation and 
reductions in LV EF. 
 
1.5.4 Is testosterone therapy safe for use in heart failure? Problem statement 
 
As indicated in preceding discussion, it is well recognised that the severity of 
increases in LV cavity volumes (LV dilatation) predict outcomes in heart failure and that 
males more frequently develop heart failure with LV dilatation (Bell et al 2013). It is 
therefore possible that longer periods of testosterone administration to males with heart 
failure than that currently evaluated (Malkin et al 2006, Camaniti et al 2009) may have 
adverse effects that have not presently been recognised. Ambiguity as to whether decreases in 
testosterone in heart failure have adverse, beneficial or neutral effects on chamber dilatation 
comes from a number of lines of evidence described in previous discussion. In summary, 
castration reduces the extent of LV cavity dimensions associated with cardiac β2-adrenergic 
receptor over-expression (Gao et al 2003) and aortic constriction (Montalvo et al 2012) in 
mice. In contrast, castration/orchiectomy worsens LV diameter in rat models of doxorubicin-
induced LV dysfunction (Sun et al 2011) and cardiomyocyte necrosis (Kang et al 2012), or 
produces no effect on LV internal diameter post myocardial infarction (Nahrendorf et al 
2003). Furthermore, testosterone replacement therapy given for 12 months to males with 
heart failure increases LV internal length (Malkin et al 2006) and testosterone administration 
for 1 month to healthy males increases LV end systolic diameter (Chung et al 2007).  
However, in all of these studies (Gao et al 2003, Sun et al 2011, Kang et al 2012, Montalvo 
et al 2012, Malkin et al 2006, Chung et al 2007, Nahrendorf et al 2003) LV chamber 
diameters were assessed using contractility, load and heart rate-dependent measures. Hence 
these findings (Gao et al 2003, Sun et al 2011, Kang et al 2012, Montalvo et al 2012, Malkin 
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et al 2006, Chung et al 2007, Nahrendorf et al 2003) may have been confounded by the 
influence of testosterone on the vasculature (hence affecting afterload) or myocardial 
contractility (Malkin et al 2010), or by the variable heart rates reported on in different 
studies. 
 
1.6 Aim of the present dissertation. 
 
To clarify whether testosterone deficiency influences the extent of LV chamber 
dilatation in cardiac disease, in the present study I therefore aimed to assess the impact of 
castration on LV diastolic pressure-volume relations in a rat model of marked LV dilatation 
induced by chronic adrenergic activation (Woodiwiss et al 2001, Osadchii et al 2007, 
Booysen et al 2012), where LV dilatation may precede a decreased LV contractility 
(Osadchii et al 2007). In support of the present dissertation, the study has been published 
(Hodson et al 2014). 
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Methods 
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2.1 Study groups  
 
The present study was approved by the Animal Ethics Screening Committee of the 
University of the Witwatersrand (clearance number: 2010/04/25). In the present study, 36, 
male Sprague Dawley rats, weighing 200-250g were assigned to one of four groups. Two 
groups of 10 rats each were employed to assess the impact of 6 months of chronic adrenergic 
activation on cardiac structure and function. Chronic adrenergic activation was produced by 
daily subcutaneous injections of the β-adrenergic receptor (β-AR) agonist, isoproterenol 
administered at a dose of 0.015mg.kg
-1
 in 0.1 mls.100g
-1
 body weight volume of 0.9% saline 
vehicle for 6 months. The remaining two groups of 8 rats each received daily injections of the 
same volume of the saline vehicle of isoproterenol for 6 months. Before beginning daily 
injections of isoproterenol or the vehicle, one group of isoproterenol-treated rats and one 
group of saline vehicle-treated rats were surgically castrated, while the remaining two groups 
were sham operated. Injections of isoproterenol or the saline vehicle were initiated two weeks 
after surgery was performed, to allow for adequate recovery from surgery. To reduce deaths 
produced by cardiac arrhythmias, the dose of isoproterenol was gradually increased from a 
starting dose of 0.001mg.kg
-1
 over a two week period. Isoproterenol, the final dose of 0.015 
mg.kg
-1
 was selected as it resulted in no further deaths. The protocol utilising a chronic low 
dose of isoproterenol is a well-established model that is considered to accurately replicate the 
pathogenesis of human heart failure (Carll et al 2011). 
However, spontaneous carcinogenesis did result in the deaths of some rats through the 
6 month duration of the study, as expected based on the known high incidence of 
carcinogenesis in Sprague Dawley rats (Davis et al 1956).  
Rats were housed in a temperature-controlled room in the Central Animal Services 
(CAS) of the University of the Witwatersrand for the duration of the project. The rats had 
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access ad libitum to both food and water, which was respectively standard rat food (supplied 
by EPOL, South Africa), and plain tap water. Animals were caged individually for the 
duration of the project. 
2.2 Surgical castration  
 
Castration was performed at approximately 10  weeks of age, as at this age the rats are 
nearing the end of hormonal adolescence. Although peripheral conversion of oestrogen to 
testosterone produces testosterone, the major source of endogenous testosterone is the testes. 
The castration and post-operative care was performed by trained and qualified technicians, 
veterinary nurses and veterinarians. Castration was performed under ketamine (80 mg.kg
-1
) 
and xylazine (20 mg.kg
-1
) general anaesthesia. Anaesthetic agents were administered via 
intraperitoneal injection. A small (approximately one centimetre) median incision was made 
at the tip of the scrotum, and the cremaster muscle exposed. The testes, caput epididymis, the 
cauda epididymis, the vas deferens, the testicular blood vessels and testicular fat were pulled 
through the incision using a blunt forceps. After clearing the fat from the bundle containing 
the vas deference and blood vessels, a single ligature was placed around the bundle, and the 
bundle was transected distal to the ligature. The testes were subsequently removed. The 
remaining bundle was subsequently replaced, haemostasis secured, and the cremaster muscle 
layer closed using a 5-0 resorbable suture. The skin was subsequently closed using a simple, 
interrupted suture with 3-0 nylon. Post-surgery, rats received Temgesic (Buprenorphine) (0.1 
mg.kg
-1
) for analgesia, and ringers lactate subcutaneously for rehydration. 
 
2.3 Body and heart weight 
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 Body weight was determined every week throughout the study. At the end of the 
study, after cardiac function had been assessed from isolated, perfused heart preparations, the 
atria were removed and heart weight (left and right ventricular weight) was evaluated. The 
right ventricular free wall as then removed from the remaining LV, and LV weight (including 
the septum) determined. To account for the impact of differences in absolute body weight or 
differences in growth on heart and LV weight, heart weight and LV weight were then indexed 
per 100 grams of body weight and per tibial length.  
 
2.4 Echocardiography 
 
Echocardiography was performed on anaesthetised rats 6 months after initiating daily 
isoproterenol or vehicle injections and 24 to 48 hours after the final administration of 
isoproterenol or its saline vehicle, using previously described methods (Norton et al 2002, 
Woodiwiss et al 2001). Echocardiography was performed at least 24 hours after the last dose 
of isoproterenol to mitigate the acute cardiovascular effects of β-AR stimulation. In this 
regard, isoproterenol produces β1-AR-mediated increases in myocardial contractility, 
myocardial relaxation, and heart rate and β2-AR-mediated vasodilator effects. Anaesthesia 
was induced via an intraperitoneal injection of 80 mg/kg ketamine and 20 mg/kg xylazine. 
These anaesthetic agents have contrasting effects on the cardiovascular system and this 
approach therefore, although not eliminating the confounding effects of anaesthesia on 
cardiovascular function, tends to limit these actions (Kreeger et al 1987). In order to perform 
echocardiography, the rat’s chest was shaved and the rat placed in a prone position on a tray 
with a window exposing the chest. A prone rather than supine position was selected for 
imaging in order to prevent hypoxia produced by compressing the chest when pushing down 
on the thoracic cavity. 
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Echocardiography was performed with a 7.0 MHz paediatric transducer connected to 
an ACUSON CYPRESS portable ultrasound device (Siemens medical division, USA, Inc). In 
this regard, a two-dimensional image was obtained of the LV in the para-sternal short-axis 
view at the level of the papillary muscle. Two-dimensional targeted M-mode 
echocardiographic images were subsequently recorded. Images were obtained only when 
both the anterior and posterior LV wall endocardial surfaces were clearly visible as this 
allows for the determination of LV diameters and posterior wall thickness values throughout 
the cardiac cycle. Images were recorded for several consecutive cardiac cycles. From these 
images, LV end diastolic (EDD) and systolic (ESD) diameters, and posterior wall thickness 
(PWT) values were determined according to the American Society for Echocardiography's 
leading edge method (Sahn and Henry 1978). An example of an echocardiographic image and 
the approach to assessing LV EDD, ESD and PWT are given in Figure 2.1. A minimum of 5 
consecutive, independent recordings were obtained to ensure both accuracy and precision.  
To determine the degree of LV dilatation using echocardiography, LV EDD was 
employed as a measure of maximal LV diameters. Nevertheless, LV EDD is sensitive to 
variations in heart rate (a decreased heart rate allows for a greater time for LV filling and 
hence an increased LV EDD), volume preload (which increases LV EDD), contractility 
(which results in a greater LV ejection and hence a reduced LV EDD), and afterload (which 
results in a reduced LV ejection and hence an increased LV EDD). As LV dilatation also 
thins the LV wall, the extent of LV remodelling was also assessed as LV relative wall 
thickness which was calculated as (2 x LV end-diastolic posterior wall thickness)/LV end-
diastolic diameter. 
To determine LV systolic function using echocardiography, LV endocardial (FSend) 
and midwall (FSmid) fractional shortening were calculated. Left ventricular FSend and 
FSmid values were employed as indices of chamber and myocardial function respectively  
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Figure 2.1 Typical two-dimensional targeted M-mode echocardiogram used to determine left 
ventricular dimensions. A: LV end diastolic internal diameter, B: LV end systolic internal 
diameter, C: LV end diastolic posterior wall thickness, D: LV end systolic posterior wall 
thickness, E: endocardium. 
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(Norton et al 2002, Chung et al 1998). Both FSend and FSmid are dependent on afterload 
(which reduced both) and heart rate (which increases both), as well as volume preload 
(Frank-Starling effect). Left ventricular FSend and FSmid were determined using the 
following formulae: 
 
FSend = 100 X (LV EDD – LV ESD) 
            LV EDD 
where: 
LV EDD = left ventricular end diastolic internal diameter 
LV ESD = left ventricular end systolic internal diameter 
 
FSmid = 100 X ((LV EDD + LVED PWT) - (LV ESD + LV ES PWT)) 
                                 (LV EDD + LV ED PWT) 
 
where: 
LVED PWT = left ventricular end diastolic posterior wall thickness 
LVES PWT = left ventricular end systolic posterior wall thickness 
 
For the calculation of FSmid, anterior wall thickness was assumed to be equivalent to 
posterior wall thickness, hence 1/2 (LV PWT) +1/2 LV anterior wall thickness was assumed 
to be equivalent to LV PWT. 
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2.5 Isolated perfused heart preparations  
 
As LV dimensions and systolic function determined by echocardiography are 
influenced by loading conditions, heart rate, anaesthetic effects, neural factors and circulating 
concentrations of positive or negative inotropic, lusitropic and chronotropic substances, I also 
determined the extent of LV dilatation and differences in systolic function ex vivo under 
controlled loading conditions and heart rate using approaches previously described (Weber 
1988, Norton 2002, Woodiwiss 2001). Immediately after echocardiography had been 
completed, a midline thoracotomy was performed under anaesthesia, the heart excised and 
placed in ice cold physiological perfusion solution to reduce cellular metabolic activity and to 
maintain viability immediately prior to perfusion (see the description of the perfusion 
solution in the subsequent discussion). Hearts were then mounted on a Langendorf perfusion 
apparatus (Figure 2.2) and retrogradely perfused via the aorta to maintain tissue viability. 
Using this approach an automatic pump is employed to generate a constant coronary flow. As 
retrograde pressure generated in the aorta closes the aortic valve, the perfusion solution 
moves through the coronary arteries rather than into the LV lumen. 
The physiological perfusion solution consisted of (in mM) 118.0 NaCl, 4.7 KCl, 2.5 
CaCl2, 25.0 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4 and 10.0 glucose with a pH of 7.4 and was 
saturated with 95% oxygen and 5% carbon dioxide gas before being filtered through a 0.45 
µm Millipore membrane. The perfusion solution was constantly gassed with a 95% oxygen 
and 5% carbon dioxide mixture for the duration of each study. Hearts were perfused at 12 
ml/g heart weight per min. Coronary flow rate was determined from timed collections of 
venous effluent. The perfusion apparatus maintained the perfusate at a constant temperature 
and free of bubbles by first passing the perfusate through a tube surrounded by a water jacket  
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Figure 2.2. Isolated, perfused heart apparatus used in ex vivo experiments to assess cardiac 
structure and function. A, pacing device; B, heated water jacket; C, bubble trap; D, three way 
tap open to E, H and I; E, pressure transducer; F, peristaltic pump; G, platinum electrodes 
attached to the isolated heart; H, fluid filled catheter attached to latex balloon which is 
inserted into the left ventricular lumen; I, micromanipulator. 
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containing water heated to 37
o
C, and then passing the perfusate through a bubble trap 
positioned proximal to the heart (Figure 2.2). 
The heart was paced at 360 beats per minute via a platinum electrode placed on the 
right atrium and a second electrode placed on the apex of the heart. Hearts were paced using a 
Grass (Astro Med Inc.) model SD9 stimulator (Figure 2.2). Hearts were paced at 360 beats 
per minute rather than at physiological rates (approximately 400-500 beats.min
-1
) in order to 
ensure that myocardial oxygen demand did not exceed supply. In this regard, although the 
physiological solution has a high oxygen partial pressure after saturating it with 95% oxygen; 
without haemoglobin, the oxygen content is below physiological levels. Nevertheless, 
previous studies conducted in the present laboratory have confirmed that a heart rate of 360 
beats.min
-1
 is appropriate to ensure that demand induced-decreases in LV function do not 
occur (Umeda et al 2003). In this regard, at heart rates above 360 beats.min
-1
, diastolic 
pressures were previously noted to begin to increase. Hearts were paced at a voltage 
estimated to be 10% above threshold for spontaneous excitation (Norton et al 2002). 
To determine the extent of LV dilatation and to assess LV systolic function, LV 
diastolic pressures and systolic developed pressures were measured over a range of LV filling 
volumes. To assess LV filling volumes, a thin walled latex balloon was passed through the 
mitral valve and placed in the LV chamber (Figure 2.3).  To assess LV diastolic pressures and 
systolic developed pressures, the latex balloon was coupled via a fluid-filled catheter to a 
Gould P50 pressure transducer (Figure 2.3). To increase LV volume the fluid-filled catheter 
was also coupled to a micromanipulator (Figure 2.3). The lumen of the balloon was large 
enough to accommodate volumes well beyond the maximum volume of the LV of either a 
normal rat or a rat with a dilated heart, and the pressure-volume relationship of the balloon 
itself only began to increase well beyond this LV volume. The volume of the balloon and 
catheter inserted into the ventricle was well below the ventricular volume at which diastolic  
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Figure 2.3. Enlargement of a portion of the isolated perfused heart apparatus depicted in 
figure 2.2. Clearly visible here are D, the three way tap; E, the pressure transducer; G, 
platinum electrodes attached to the isolated heart; H, the fluid filled catheter connected to the 
balloon in the left ventricular lumen and I, the micromanipulator. 
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pressures begin to increase, and the balloon material volume was added to balloon fluid 
volume to determine actual LV volume. Before placing the balloon into the LV cavity, the 
balloon was emptied of all excess volume by removing the micromanipulator, opening the 
three-way valve to atmosphere and squeezing excess fluid from the balloon via the catheter. 
Left ventricular pressures were determined at as many small increments in volume as were 
practically possible. As the micromanipulator has a Vernier scale, it allows for 0.005 to 0.01 
ml increments in volume to the balloon. The micromanipulator was regularly calibrated by 
weighing 0.005 to 0.01 ml increments of distilled H2O. Left ventricular developed pressures 
and diastolic pressures were recorded on a Hellige polygraph recorder (Figure 2.4). 
Calibration of the recorded LV developed pressures was performed using a mercury 
manometer, and LV diastolic pressures using a water-filled U-tube system designed to 
calibrate low pressure systems (Norton et al 1996). I performed calibrations for both LV 
developed pressure and diastolic pressure recordings after each heart preparation. As the 
isolated perfused heart preparation used in this dissertation is isovolumic, I assumed that LV 
minimum pressures (diastolic pressures) were equivalent to LV end diastolic pressure (Figure 
2.4). Left ventricular developed pressures were calculated as the difference between peak LV 
systolic pressure and diastolic pressure (Figure 2.4). 
To determine the extent of LV dilatation using a load-independent measure, LV 
diastolic pressure-volume relations were constructed. For statistical comparisons, the volume 
intercept at a diastolic pressure of 0 mm Hg (LV V0) was identified (Badenhorst et al 2003a, 
Badenhorst et al 2003, Woodiwiss et al 2001, Norton et al 2002). 
To assess LV systolic chamber function, LV developed pressure-volume relations 
were constructed and the slope of the linear portion of the relationship evaluated (LV systolic 
elastance-LV E) (Badenhorst et al 2003a, Badenhorst et al 2003b, Woodiwiss et al 2001, 
Norton et al 2002). Importantly LV Ees is the equivalent of LV end systolic elastance in an  
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Figure 2.4. Typical recording of left ventricular developed pressure (LVDP) and diastolic 
developed pressure (LVEDP) pressure obtained in isolated perfused heart preparations over a 
range of filling volumes. 
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ejecting and filling LV, a well-established afterload and preload-independent measure of LV 
systolic chamber function (Sagawa et al 1981, Sagawa et al 1988). Data points were included 
in the LV systolic developed pressure-volume relationship if on linear regression analysis for 
individual rats, the r
2
 value for the relationship was 0.95 or more. Using this approach, the 
first 5 LV developed pressures were included in the relationships for all rats. 
To assess LV systolic intrinsic myocardial function, LV developed stress and strain 
relationships were constructed and the slope of the relationships evaluated (LV myocardial 
systolic elastance-En) (Norton et al 2002, Badenhorst et al 2003b, Veliotes et al 2005). By 
converting developed pressure and volume into stress and strain data, differences in the 
impact of LV geometry on systolic chamber function are accounted for and hence the slope 
of the stress-strain relationship can only be determined by intrinsic myocardial systolic 
function (Weber et al 1988). Although stress and strain relationships are linear along any 
portion of the relationships, many data points can be included for the calculation of En. 
However, to ensure that calculations of En were representative of the data obtained for E, En 
was calculated using only the matching ventricular developed pressure and volume data used 
to calculate E. Left ventricular stress and strain were calculated assuming a thick walled 
spherical geometry of the heart, from previously described formulae (Weber et al 1988, 
Norton et al 2002, Badenhorst et al 2003b, Veliotes et al 2005) as follows: 
 
Left ventricular systolic stress  =
Left ventricular systolic strain  =
1.36 x LV developed pressure x (LVV)2/3
[LVV + (0943 x LV mass)]2/3 – LVV2/3
LVV1/3 + [LVV + (0.943 x LV mass)]1/3]-1
LV V0
1/3 + [LV V0 + (0.943 x LV mass)]
1/3
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Where LVV is left ventricular volume and LV V0 is the volume intercept of the LV 
developed pressure-volume relationship (LVV when LV developed pressure = 0 mm Hg). 
 
2.6 Data analysis  
 
A two-way ANOVA with a Tukey post hoc test was employed to determine the effect 
of castration or sham surgery, and 6 months of daily isoproterenol or saline administration on 
body weight, heart weight and LV structure and function. Linear regression analysis to 
determine the line of best fit for cardiac function. All values are presented as mean±SEM. 
Significant values were detected if p<0.05. The statistical software employed were SAS, 
version 9.3 (SAS institute Inc., Cary NC), and Prism version 5.02 (GraphPad Software Inc.). 
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Results 
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3.1 Effects of castration and chronic adrenergic stimulation on body and heart 
weight.  
 
Chronic isoproterenol administration to rats failed to modify either body or heart 
weight (Table 3.1). Castration resulted in a decrease in body weight and this effect was 
similar in saline- or isoproterenol-treated groups (Table 3.1). However, castration failed to 
influence either heart weight or LV weight in either saline- or isoproterenol-treated rats 
(Table 3.1). Importantly, the lack of effect of castration on heart weight or LV weight were 
noted irrespective of whether heart weight was expressed per 100 g body weight or per tibial 
length (Table 3.1).  
 
3.2 Effects of castration on adrenergic-induced LV dilatation. 
 
As compared to saline-treated rats, chronic isoproterenol administration resulted in an 
increased LV end diastolic (EDD) and end systolic (ESD) diameter (Table 3.2), a right shift 
in the LV diastolic pressure-volume relationship (Figure 3.1), and an increased volume 
intercept of the LV diastolic pressure-volume relationship (LV V0, Figure 3.1). Castration 
failed to influence adrenergic-induced changes in either LV EDD or ESD (Table 3.2), the LV 
diastolic pressure-volume relationship (Figure 3.1), or LV V0 (Figure 3.1). 
 
3.3 Effects of castration on adrenergic-induced LV systolic chamber and myocardial 
function. 
 
As compared to saline-treated rats, chronic isoproterenol administration failed to 
influence systolic chamber function as assessed in vivo from a load-dependent measurements  
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Table 3.1. Impact of castration and chronic β-adrenergic receptor stimulation (daily 
isoproterenol injections for 6 months [ISO]) on body and heart weight in rats. 
 
 
Sham-operated 
 
Castrated 
 Saline vehicle ISO Saline vehicle ISO 
n = 8 10 8 9 
Body weight (BW) 
(g) 
633.0 ± 28.5 623.6 ± 15.2 535.5 ± 17.2* 536.6 ± 14.1* 
Heart weight (HW)(g) 1.48 ± 0.08 1.65 ± 0.08 1.47 ± 0.08 1.41 ± 0.11 
LV weight (g) 1.19 ± 0.06 1.34 ± 0.14 1.16 ± 0.07 1.13 ± 0.10 
HW/BW x 100 0.24 ± 0.02 0.26 ± 0.03 0.28 ± 0.02 0.26 ± 0.03 
LV/BW x 100 0.19 ± 0.01 0.22 ± 0.03 0.22 ± 0.01 0.21 ± 0.02 
HW/tibial length 0.30 ± 0.02 0.35 ± 0.03 0.31 ± 0.02 0.29 ± 0.02 
LV/tibial length 0.24 ± 0.02 0.28 ± 0.04 0.24 ± 0.02 0.23 ± 0.02 
LV, left ventricular; *p<0.0001 versus Sham-operated groups. 
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Table 3.2. Impact of castration on changes in left ventricular diameters as assessed in vivo 
(echocardiography) following chronic β-adrenergic receptor stimulation (daily isoproterenol 
injections for 6 months [ISO]). 
 
 Sham-operated Castrated 
 Saline vehicle ISO Saline vehicle ISO 
n = 8 10 8 9 
LV EDD (mm) 7.91 ± 0.24 9.05 ± 0.16* 7.92 ± 0.17 8.45 ± 0.14* 
LV ESD (mm) 4.38 ± 0.24 5.34 ± 0.24* 4.32 ± 0.21 4.91 ± 0.12* 
___________________________________________________________________________ 
LV, left ventricular; EDD, end diastolic diameter; ESD, end systolic diameter; *p<0.05 
versus saline-treated groups. 
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Figure 3.1. Impact of castration on changes in left ventricular (LV) diastolic pressure-volume 
relations following chronic β-adrenergic receptor stimulation (daily isoproterenol injections 
for 6 months [ISO]). The lower panel shows the volume intercept at 0 mmHg diastolic 
pressure (LV V0), an index of the extent of LV remodelling.  
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(LV FSend)(Table 3.3), as well as ex vivo from the LV end systolic developed pressure-
volume relationship and the load-independent slope of this relationship (LV Ees)(Figure 3.2). 
Moreover, chronic adrenergic stimulation did not impact on systolic myocardial function as 
assessed either in vivo from a load-dependent measurement (LV FSmid)(Table 3.3), or ex vivo 
from the LV end systolic developed stress-strain relationship and the load-independent slope 
of this relationship (LV En)(Figure 3.3). Castration did not influence the load-dependent 
measures of systolic chamber (FSend) or myocardial (FSmid) function (Table 3.3). 
Furthermore, castration did not modify the LV end systolic developed pressure-volume 
(Figure 3.2) or stress-strain (Figure 3.3) relationships and the load-independent slopes of 
these relationships (LV Ees and LV En, Figures 3.2 and 3.3). 
58 
 
Table 3.3. Impact of castration on changes in left ventricular systolic function as assessed in 
vivo (echocardiography) following chronic β-adrenergic receptor stimulation (daily 
isoproterenol injections for 6 months [ISO]). 
 
 Sham-operated Castrated 
 
Saline 
vehicle 
ISO 
Saline 
vehicle 
ISO 
n = 8 10 8 9 
LV FSend (%) 44.90 ± 1.68 41.18 ± 1.86 45.61 ± 2.07 41.81 ± 1.28 
LV FSmid (%) 27.13 ± 1.03 26.85 ± 2.50 27.54 ± 0.78 26.59 ± 0.95 
FSend, endocardial fractional shortening; FSmid, midwall fractional shortening. 
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Figure 3.2. Impact of castration and chronic β-adrenergic receptor stimulation (daily 
isoproterenol injections for 6 months [ISO]) on the linear portion of the LV developed 
pressure-volume relationship and the slope of this relationship (LV Ees), a load-independent 
index of LV systolic chamber function. 
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Figure 3.3. Impact of castration and chronic β-adrenergic receptor stimulation (daily 
isoproterenol injections for 6 months [ISO]) on the LV systolic stress-strain relationship and 
the slope of this relationship (LV En), a load-independent index of LV systolic myocardial 
function. 
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Chapter 4 
 
 
Discussion 
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4.0 Summary of main findings 
 
The main finding of the present study is that castration, despite producing marked 
decreases in body weight, had no influence on LV dilatation produced by chronic β-
adrenergic stimulation in rats. Importantly, in the present study LV dilatation was assessed 
using a load-, heart rate-, and contractility-independent measure (LV diastolic pressure-
volume relation). In addition, the lack of effect of castration on LV dilatation was noted prior 
to the development of decreases in LV systolic chamber or myocardial function as assessed 
using load-independent measurements (LV Ees, LV En).  
 
4.1 Testosterone deficiency and LV dilatation  
 
To the best of my knowledge the present study provides the first direct evidence that 
testosterone deficiency does not affect LV dilatation associated with chronic adrenergic 
activation. In this regard, a number of prior studies have reported on the effect of 
orchiectomy or castration on LV diameters in chronic cardiac disease and produced 
discrepant results (Gao et al 2003, Cavasin et al 2003, Montalvo et al 2012, Sun et al 2011, 
Kang et al 2012, Nahrendorf et al 2003, Jain et al 2002, Thireau et al 2010). 
Although in some studies castration has been demonstrated to produce protective 
effects against increases in LV diameters in chronic mice models of cardiac disease 
associated with cardiac β2-adrenergic receptor over-expression (Gao et al 2003, Thireau et al 
2010)
 
or aortic constriction (Montalvo et al 2012), and in a rat model of MI (Cavasin et al 
2003), castration/orchiectomy has also been shown to augment increases in LV diameters in 
rat models of cardiomyocyte necrosis (Kang et al 2012) and, or produce no effect on LV 
diameters in a rat model post myocardial infarction (Nahrendorf et al 2003) and doxorubicin-
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induced LV cardiomyopathy and dysfunction (Sun et al 2011). However, in all of these prior 
studies (Gao et al 2003, Cavasin et al 2003, Montalvo et al 2012, Sun et al 2011, Kang et al 
2012, Nahrendorf et al 2003, Jain et al 2002, Thireau et al 2010), the method of assessing LV 
dilatation (i.e. LV diameter) is load-, heart rate- and contractile function-dependent. Hence, 
the diverse findings may relate to the impact of castration or the animal model studied on any 
one of these haemodynamic changes. In contrast, I show no effect of castration on 
adrenergic-induced right shifts in LV diastolic pressure-volume relations as assessed at 
controlled heart rates. In this regard, this measurement of adverse LV remodelling is not 
subject to variations in heart rate, LV contractility or LV afterload. 
The ability of castration to attenuate increases in LV diameters in some studies (Gao 
et al 2003, Cavasin et al 2003, Montalvo et al 2012, Thireau et al 2010)
 
may be secondary to 
the ability to protect against systolic chamber dysfunction in these models. Indeed, as 
outlined in section 1.5.1 of the introductory chapter, an improved myocardial contractility 
may occur subsequent to castration in these studies (Gao et al 2003, Cavasin et al 2003, 
Montalvo et al 2012) and consequently an increased systolic chamber function, could have 
increased ventricular ejection and hence reduced LV EDD. In contrast, an ability of 
orchiectomy/castration to exacerbate increases in LV diameters in other studies (Sun et al 
2011, Kang et al 2012)
 
may be secondary to worsening of systolic chamber function in the 
latter models. Indeed, a reduced myocardial contractility subsequent to castration in these 
studies (Gao et al 2003, Montalvo et al 2012) and consequently a decreased systolic chamber 
function, could have decreased ventricular ejection and hence enhanced LV EDD. However, 
unlike these prior studies (Gao et al 2003, Cavasin et al 2003, Montalvo et al 2012, Sun et al 
2011, Kang et al 2012, Jain et al 2002, Thireau et al 2010) where LV EDD changes 
subsequent to castration may have been secondary to modifications in systolic chamber 
function, I report on a lack of effect of castration on the LV diastolic pressure-volume 
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relation, prior to the development of systolic chamber dysfunction as assessed from LV Ees 
and LV En. Hence, the present study provides strong evidence to suggest that testosterone 
deficiency has little effect on the primary remodelling process responsible for LV dilatation 
in cardiac disease. 
One possibility to explain the lack of effect of castration on LV dilatation in the 
present study is that although castration resulted in marked decreases in body weight this 
failed to translate into decreases in heart weight. In this regard, LV dilatation may be 
associated with increases in LV weight and hence decreases in heart weight may be required 
to return LV diameters to normal. Indeed, Gao et al (2003) and Thireau et al (2010) reported 
on a beneficial effect of castration on adrenergic-induced LV dilatation in association with a 
decrease in heart weight indexed for body weight. Moreover, in a number of studies that 
failed to show a beneficial effect of castration on LV dilatation in animal models of LV 
dilatation associated with cardiomyocyte necrosis (Kang et al 2012), MI (Nahrendorf et al 
2003) or doxorubicin-induced myocardial damage (Sun et al 2011), castration also failed to 
reduce heart weight. However, despite a beneficial effect of castration on LV diameters in a 
model of aortic constriction, castration failed to decrease heart weight (Montalvo et al 2012). 
Hence, although there is a possibility that reductions in heart weight are required for 
castration to reduce LV cavity dimensions, this does not appear to be the only factor 
involved.  
A caveat of the present study is that I did not show that LV dilatation ultimately 
translates into a reduced LV systolic chamber function following chronic β-AR activation. 
Hence, it may be argued that the neutral effect of testosterone deficiency on LV dilatation 
observed in the present study, does not preclude the possibility that testosterone replacement 
therapy in heart failure does not ultimately worsen LV dilatation associated with systolic 
chamber dysfunction. However, our research group has previously demonstrated that with 
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daily administration of modestly higher doses of isoproterenol than that given in the present 
study, that LV dilatation is indeed associated with the development of LV systolic chamber 
dysfunction (a reduced LV end systolic elastance) (Woodiwiss et al 2001, Osadchii et al 
2007, Booysen et al 2012). Moreover, the association between LV dilatation and LV systolic 
chamber dysfunction in these prior studies was noted to be a key mechanism responsible for 
the reduced systolic chamber function (Osadchii et al 2007, Booysen et al 2012). Indeed, LV 
systolic chamber dysfunction in these prior studies (Osadchii et al 2007, Booysen et al 2012) 
occurred in the absence of changes in LV En (myocardial systolic dysfunction). Hence, it is 
likely that the LV dilatation evaluated in the present study does indeed have important 
pathophysiological implications. 
 
4.2 Testosterone deficiency and LV systolic chamber function. 
 
An important consideration is that the testosterone deficiency that is likely to have 
been produced by castration in the present study failed to influence either LV systolic 
chamber function or LV intrinsic myocardial systolic function in either normal rats or in rats 
exposed to chronic adrenergic activation. To this effect, the previous studies investigating the 
effect of testosterone withdrawal or replacement on cardiac function show discrepant results 
(Cavasin et al 2003, Montalvo et al 2012, Sun et al 2011, Kang et al 2012, Jain et al 2002, 
Sebag et al 2011, Curl et al 2008, Golden et al 2003). What could explain these 
discrepancies? 
One possible explanation for the discrepancies between studies evaluating the impact 
of castrations on cardiac systolic function, is the differences in the models studied. In this 
regard, Sun et al (2011) and Kang et al (2012) made use of acute models of myocardial 
toxicity and in both instances castration caused a greater degree of cardiac systolic 
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dysfunction, while post-castration treatment with testosterone ameliorated the effect of 
castration. In contrast, Gao et al (2003) and Thireau et al (2010) employed models of 
adrenergic-induced cardiac dysfunction and Montalvo et al (2012) studied an animal model 
of aortic constriction and demonstrated beneficial effects of castration. Hence, it is possible 
that castration has different effects on the adverse actions of acute (Montalvo et al 2012) as 
opposed to more chronic (Gao et al 2003, Thireau et al 2010) myocardial changes. However, 
studies evaluating the impact of castration on cardiac function post-MI, where the pathology 
may be considered to be a combination of acute and chronic myocardial damage has been 
shown to produce both beneficial (Cavasin et al 2006) and neutral (Nahrendorf et al 2003) 
effects. Therefore it is difficult to ascribe the differential effects of castration on systolic 
cardiac function in animal models of cardiac pathology on the different models of disease 
studied. 
 
4.3 Effects of castration of cardiac weight 
 
An important question which arises from the present study is why castration resulted 
in reductions in heart weight in some but not other studies (including the present study)? In 
this regard, the timing of castration may be considered as being important. In one study 
where heart weight was reduced by castration, castration was performed at three weeks of 
age, a point clearly before the onset of adolescence (Thireau et al 2010). Moreover, Montalvo 
et al (2012) failed to show an effect on heart weight when mice were castrated at one year of 
age, an age well into sexual maturity. In contrast however, in a study where castration 
resulted in a decrease in heart weight, castration was only performed at 3 months of age (Gao 
et al 2003), an age that is well past the onset of adolescence in murine models. Furthermore, 
Cavasin et al (2006) orchidectomized mice at four weeks of age, and Nahrendorf et al (2003) 
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similarly orchidectomized animals at a very young age, and neither group of authors showed 
effects on heart weight. Moreover, in the present study I similarly castrated pre-pubescent 
rats and despite a marked effect on body weight, failed to show an impact of castration on 
heart weight (Hodson et al 2014). Hence, further studies are required to attempt to explain 
discrepancies in the impact of castration on heart weight. 
 
4.4 Potential clinical implications 
 
The clinical importance of the present study warrants consideration. Although 
testosterone deficiency in heart failure is independently associated with a poor prognosis 
(Jankowska et al 2006, Güder et al 2010, Kontoleon et al 2003), no obvious or only minor 
effects on the LV are noted when testosterone is administered up to 12 months in patients 
with heart failure (Malkin et al 2006, Caminiti et al 2009). However, longer periods of 
testosterone replacement therapy in patients with heart failure than that already assessed (1-
12 months) (Malkin et al 2006, Chung et al 2007) may have adverse effects on LV dilatation. 
Thus, whether the benefits of testosterone replacement therapy in patients with heart failure 
on skeletal muscle strength, lean muscle mass, endurance, and neuromuscular and 
baroreceptor reflexes (Malkin et al 2010) could be exploited for prolonged periods is 
unknown. The present study provides some confidence that testosterone deficiency has no 
protective benefits on LV dilatation and hence that testosterone replacement therapy raised to 
normal levels is unlikely to produce adverse consequences to the primary LV remodelling 
process in chronic cardiac disease. 
There is an important caveat to the present study, with major clinical implications, 
that requires consideration. Orchiectomy/castration has been demonstrated to produce 
protective effects against LV systolic function in mice models of cardiac disease associated 
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with cardiac β2-adrenergic receptor over-expression (Gao et al 2003) or aortic constriction 
(Montalvo et al 2012). Thus, there is still a possibility that testosterone replacement therapy 
may produce adverse effects on cardiac function in heart failure associated with pressure-
overload states or when inadequate adrenergic receptor blockade occurs, but most likely in 
heart failure with an intrinsic cardiomyopathy (Sun et al 2011, Kang et al 2012). Further 
clinical studies are therefore required to assess the impact of testosterone replacement therapy 
on pressure-overload-induced cardiac failure or in patients unable to tolerate adequate doses 
of β-adrenergic receptor blocking agents. 
 
4.5 Does the present study contribute toward our current understanding of gender 
differences in cardiac structure and function? 
 
Although not an aim of the present study it is worth considering whether the present 
study contributes toward our present understanding of the gender differences which exist in 
cardiac structure and function in either healthy individuals or in cardiac disease. As discussed 
in chapter 1, there is considerable evidence to suggest that males have a more eccentric LV 
than females and that this translates into reductions in LV systolic chamber function (see 
sections 1.3 and 1.4). Moreover, in heart failure or cardiac disease, males are more likely to 
develop a greater degree of LV dilatation than females and this translates into a greater 
chance of developing a reduction in LV systolic chamber function in males as compared to 
females (see sections 1.3 and 1.4). In this regard, it is well recognised that LV dilatation is 
produced by neurohumoral activation in heart failure (see section 1.2.5). Hence, one possible 
factor which may account for gender differences in LV dimensions and systolic chamber 
dysfunction is through an interaction between testosterone and adverse sympathetic effects on 
the heart.  However, as indicated in section 1.5.2 of chapter 1, studies investigating the 
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relationship between gender and adrenergic stimulation in pathology, report potentially 
beneficial or detrimental actions of male gender and testosterone depending on the pathology 
involved. Does the current study support or oppose these data? 
Myocardial adrenergic down-regulation may have adverse effects in chronic heart 
failure. Indeed, after four weeks of volume overload induced via an arterio-venous fistula, in 
which eccentric LV remodelling was clearly detected in male but not female rats, a reduction 
of β1-adrenergic receptor mRNA expression was noted in male rats as compared to their 
controls, whilst female rats had no such reduction (Dent et al 2010, Dent et al 2011). 
Furthermore, β2-adrenergic receptor mRNA expression was increased in female hearts 
relative to control animals, but not in males and β1 and β2-adrenergic receptor density and 
concentration was reduced in male hearts, whilst they were conversely increased in female 
hearts (Dent et al 2011). Whether these myocardial adrenergic changes in male rats represent 
a compensatory response to protect the myocardium against excessive adrenergic stimulation, 
or whether they contribute toward LV dilatation and reductions in systolic chamber function 
is uncertain. In this regard the present study suggests that if these changes are attributed to an 
interaction between sympathetic stimulation and testosterone (Dent et al 2010, Dent et al 
2011), that they are unlikely to contribute toward LV dilatation and systolic chamber 
dysfunction. 
In studies involving transgenic mice with β2-adrenergic receptor overexpression, male 
mice have been noted to develop increased LV diameters and a reduced LV EF relative to the 
female mice (Gao et al 2003, Thireau et al 2010). Furthermore, gonadectomy in male mice 
reduced LV diameters and increased LV EF (Gao et al 2003, Thireau et al 2010). These data 
suggest that at least in the context of excessive β2-adrenergic receptor over-activation, 
testosterone interacts with the adrenergic stimulus to enhance the adverse effects of 
adrenergic activation on adverse LV remodelling and LV EF. However, the present results 
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challenge this hypothesis and suggest that if an interaction between testosterone and 
sympathetic stimulation contributes toward adverse LV remodelling, that this effect must be 
secondary to the deleterious effects of adrenergic actions on myocardial systolic function, 
which will cause cardiac dilatation secondary to reductions in chamber contraction.    
 
4.6 Limitations of the present study 
 
The potential limitations of the present study warrant consideration. First, although I 
demonstrated that castration was unable to modify LV dilatation mediated by chronic excess 
adrenergic receptor activation, I did not assess the impact on the mechanisms that contribute 
toward adrenergic-induced LV dilatation. In this regard, the current findings could have been 
further supported by measurements of myocardial collagen characteristics (Gunja-Smith et al 
1996, Badenhorst et al 2003a, Lindsey et al 2003, Weber et al 1988), and apoptosis 
(Communal et al 1998, Fan et al 2006, Garg et al 2005). Nevertheless, even if castration had 
modified any of the basic mechanisms involved in mediating cardiac dilatation, these changes 
clearly failed to translate into changes in the adverse LV diastolic remodelling process. 
Second, as already acknowledged, I did not assess the impact of castration on a model of 
adrenergic-induced LV dilatation with systolic chamber dysfunction. However, as explained 
in the aforementioned discussion, this allowed for the assessment of the impact of castration 
on LV dilatation prior to systolic chamber decompensation. Hence, an interpretation of the 
data without the confounding influence of systolic chamber dysfunction on LV dilatation was 
possible. Third, LV diastolic pressure-volume relations were determined in an isovolumic 
cardiac preparation, which does not allow for separation of early and late diastolic phases of 
the cardiac cycle. In this regard the factors which determine early and late diastolic pressure-
volume relations are likely to differ (Gibert and Glantz 1989). Fourth, the extent to which 
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castration reduced circulating testosterone concentrations was not assessed. Nevertheless, 
although peripheral conversion of oestrogen to testosterone produces testosterone, the major 
source of endogenous testosterone is the testes. Evidence in favour of marked testosterone 
deficiency following castration was the presence of an almost 100g difference in body weight 
between sham-operated and castrated rats at the end of the study.  
 
4.7 Conclusions 
 
In conclusion, the present study shows that castration has no effect on right shifts in 
LV diastolic pressure-volume relations produced by chronic β-adrenergic receptor 
stimulation. The lack of effect of castration on LV diastolic pressure-volume relations was 
noted prior to the development of decreases in LV systolic function as assessed using load-
independent measurements. Hence, the present results provide the first direct evidence to 
suggest that testosterone deficiency in chronic cardiac disease has no effect on the primary 
mechanisms responsible for LV dilatation. Thus, chronic testosterone replacement therapy in 
heart failure may not exacerbate adverse LV remodelling. In support of the present 
dissertation, the study has been published (Hodson et al 2014). 
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